Zymeworks signed a cope with Jazz Prescription drugs to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, which targets the most cancers marker HER2. Zymeworks will obtain an upfront cost of $50 million and a second cost of $325 million, at Jazz’s possibility, following the discharge of topline knowledge from an ongoing scientific trial. That…
